Information:
Fel:
ID
16817
Beskrivning
CFAR Study in Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00525603
Länk
https://clinicaltrials.gov/show/NCT00525603
Nyckelord
Versioner (1)
- 2016-08-08 2016-08-08 -
Uppladdad den
8 augusti 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Leukemia NCT00525603
Eligibility Leukemia NCT00525603
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00525603
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Untreated chronic lymphocytic leukemia
Item
all patients must have a diagnosis of cll by immunophenotyping and flow cytometry analysis of blood or bone marrow and be previously untreated.
boolean
C0023434 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,2])
Age, serum beta-2 microglobulin
Item
all patients must be younger than 70 years and have a serum beta-2 microglobulin of >/= 4.0mg/l.
boolean
C0001779 (UMLS CUI [1])
C0201910 (UMLS CUI [2])
C0201910 (UMLS CUI [2])
Rai stage
Item
all patients with rai stage iii-iv are eligible for treatment on this protocol. - or- all patients with rai stage 0-ii who meet one or more indication for treatment as defined by the nci-sponsored working group are eligible for treatment on this protocol.
boolean
C1514715 (UMLS CUI [1])
Zubrod Performance Status
Item
all patients must have a zubrod performance status of 0-3.
boolean
C3714786 (UMLS CUI [1])
renal and hepatic function
Item
all patients must have adequate renal and hepatic function (serum creatinine </= 2mg/dl; total bilirubin </= 2.5mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the principle investigator and appropriate dose adjustment considered.
boolean
C0201976 (UMLS CUI [1])
C0201913 (UMLS CUI [2])
C0201913 (UMLS CUI [2])
Concurrent Chemotherapy, Radiotherapy, or Immunotherapy
Item
patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy. localized radiotherapy to an area not compromising bone marrow function does not apply, nor do hematopoietic growth factors such as erythropoietin, granulocyte colony-stimulating factor (g-csf), granulocyte-macrophage colony stimulating factor (gm-csf), etc.
boolean
C0009429 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0009429 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3,1])
C0021083 (UMLS CUI [3,2])
C0392920 (UMLS CUI [1,2])
C0009429 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3,1])
C0021083 (UMLS CUI [3,2])
Infection
Item
patients must not have untreated or uncontrolled life-threatening infection.
boolean
C0009450 (UMLS CUI [1])
Informed consent
Item
patients must sign informed consent.
boolean
C0021430 (UMLS CUI [1])
Age
Item
patients older than 70 years.
boolean
C0001779 (UMLS CUI [1])